Related Experiment Videos
Kidney cancer therapy: new perspectives and avenues
Doru T Alexandrescu1, Constantin A Dasanu
1Georgetown University, Washington Cancer Institute, 110 Irving Street, N.W., Washington, DC 20010, USA. mddoru@hotmail.com
Abstract:
Immunotherapy with interleukin-2 and interferon-alpha has been the only viable option in metastatic renal cell cancer for almost two decades. In the last several years, significant advances in the understanding of the underlying biological and molecular mechanisms of renal cell carcinoma, particularly the role of tumour angiogenesis, have led to the identification of rational therapeutic targets and permitted the design of molecularly targeted therapeutics. At present, new compounds targeting specific signalling pathways are available and have successfully passed clinical testing. The use of small molecules, such as multitargeted tyrosine kinase inhibitors, the mTOR inhibitors and monoclonal antibodies, is dramatically changing the existing concepts of systemic treatment for metastatic kidney cancer.
Insights
For decades, interleukin-2 and interferon-alpha were the only treatments for metastatic kidney cancer. Now, targeted therapies like kinase inhibitors are revolutionizing treatment options.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Metastatic renal cell carcinoma (mRCC) treatment was limited to immunotherapy (interleukin-2 and interferon-alpha) for nearly 20 years.
- Recent advances in understanding mRCC biology, especially tumor angiogenesis, have identified new therapeutic targets.
Purpose of the Study:
- To review the shift in systemic treatment paradigms for metastatic kidney cancer.
- To highlight the emergence and impact of molecularly targeted therapeutics in mRCC.
Main Methods:
- Review of recent clinical trial data and scientific literature.
- Analysis of novel therapeutic agents targeting specific signaling pathways in mRCC.
Main Results:
- New molecularly targeted therapies have demonstrated efficacy in clinical testing.
- Small molecules, including multitargeted tyrosine kinase inhibitors and mTOR inhibitors, alongside monoclonal antibodies, are now available.
Conclusions:
- The treatment landscape for metastatic kidney cancer is rapidly evolving.
- Targeted therapies are replacing older immunotherapy approaches, offering new hope for patients with mRCC.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Kidney Structure
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
The Behavioral Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...